• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

McKesson/HBOC bites back at shareholders who sued

Article

McKesson/HBOC has filed a countersuit against shareholders who sued the company after its stock took a nosedive in mid-1999 (HNN 10/18/00). McKesson/HBOC stock lost $9 billion in value in one day after revelation of a financial scandal

McKesson/HBOC has filed a countersuit against shareholders who sued the company after its stock took a nosedive in mid-1999 (HNN 10/18/00). McKesson/HBOC stock lost $9 billion in value in one day after revelation of a financial scandal involving Albert Bergonzi and Jay Gilbertson, co-presidents and co-chief operating officers for HBOC before the merger of McKesson and HBOC.

The two men were indicted in October by the U.S. Securities and Exchange Commission on 17 counts of securities fraud, conspiracy, mail fraud, and wire fraud for falsifying company ledgers to boost HBOC profits prior to the merger in January 1999. When McKesson/HBOC announced in April 1999 that it would have to restate several years' worth of earnings reports, the company's stock fell from around $66 per share to $34.50 in one day. This prompted the shareholder lawsuit.

McKesson/HBOC's countersuit, however, alleges that stockholders were "unjustly enriched" before the stock crash and that the company was victimized as well. While the shareholder complaint claims that McKesson knew about HBOC's financial finagling before finalizing its purchase of HBOC, McKesson denies the charge.

Recent Videos
Emerging Research at SNMMI Examines 18F-flotufolastat in Managing Primary and Recurrent Prostate Cancer
Could Pluvicto Have a Role in Taxane-Naïve mCRPC?: An Interview with Oliver Sartor, MD
New SNMMI President Cathy Cutler, PhD, Discusses Current Challenges and Goals for Nuclear Medicine
Where the USPSTF Breast Cancer Screening Recommendations Fall Short: An Interview with Stacy Smith-Foley, MD
A Closer Look at MRI-Guided Transurethral Ultrasound Ablation for Intermediate Risk Prostate Cancer
Improving the Quality of Breast MRI Acquisition and Processing
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Related Content
© 2024 MJH Life Sciences

All rights reserved.